WHIM Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | NIAID, X4 Pharmaceuticals

DelveInsight's "WHIM Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the WHIM, historical and forecasted epidemiology as well as the WHIM market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover which therapies are expected to grab the WHIM Syndrome Market Share @ WHIM Syndrome Market Outlook- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the WHIM Syndrome Market Report
• In April 2025, X4 Pharmaceuticals announced a study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
• The total diagnosed prevalent cases of WHIM in the US comprised approximately 121 in 2023 and are projected to increase during the forecast period.
• As per DelveInsight's estimates, the US alone accounts the highest number of total diagnosed prevalent cases, of WHIM in the 7MM, followed by EU4 and the UK and Japan, contributing to 27% and 6% of all WHIM cases respectively.
• Forecast assessments suggest a growing prevalence of diagnosed WHIM syndrome cases, projecting an increase to approximately 48 males and 73 females by 2023 in the US. This trend reflects an anticipated rise in both genders over the forecast period.
• EU4 and the UK accounted for around 48 diagnosed prevalent cases of WHIM in 2023. Of these cases, France accounted for the highest number of cases.
• The leading WHIM Syndrome Companies such as NIAID, X4 Pharmaceuticals, and others.
• Promising WHIM Syndrome Pipeline Therapies such as X4P-001, Mavorixafor, and others.

Stay ahead in the WHIM Syndrome Therapeutics Market with DelveInsight's Strategic Report @ WHIM Syndrome Market Outlook- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

WHIM Syndrome Epidemiology Segmentation in the 7MM
• Total WHIM Syndrome Incident Cases
• WHIM Syndrome Age-specific Diagnosed Prevalent Cases
• WHIM Syndrome Gender-specific Cases

Download the report to understand which factors are driving WHIM Syndrome Epidemiology trends @ WHIM Syndrome Prevalence- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

WHIM Syndrome Marketed Drugs
• XOLREMDI (mavorixafor): X4 Pharmaceuticals
XOLREMDI (mavorixafor) is the first FDA approved capsules indicated in patients with WHIM syndrome promising first-in-class, oral small molecule, functioning as a selective CXCR4 receptor antagonist. This drug enhances the mobilization and trafficking of white blood cells from the bone marrow. Beyond WHIM syndrome, Mavorixafor is being explored for severe congenital neutropenia (SCN), Waldenström's macroglobulinemia, breast cancer, malignant melanoma, and clear cell renal cell carcinoma (ccRCC).

Emerging WHIM Syndrome Drugs
• Plerixafor: National Institute of Allergy and Infectious Diseases (NIAID)
Plerixafor (MOZOBIL, AMD3100), approved by the US FDA, mobilizes CD34+ hematopoietic stem cells for autologous transplantation in non-Hodgkin's lymphoma and multiple myeloma patients. It also addresses WHIM syndrome by partially blocking CXCR4, used at lower doses than for stem cell mobilization. The National Institute of Allergy and Infectious Diseases is advancing plerixafor for WHIM syndrome, which has completed Phase III trials. Its mechanism involves specific, reversible inhibition of the CXCR4 receptor, disrupting the binding of stromal cell-derived factor-1 (SDF-1) and affecting cellular adhesion.

To learn more about WHIM Syndrome Treatment guidelines, visit @ WHIM Syndrome Treatment Market Landscape- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

WHIM Syndrome Companies
NIAID, X4 Pharmaceuticals, and others.

WHIM Syndrome Market Outlook
WHIM Syndrome treatment includes both pharmacological and non-pharmacological approaches. Pharmacological treatments primarily involve Plerixafor (MOZOBIL), a CXCR4 receptor antagonist that helps manage neutropenia by partially blocking CXCR4 signaling. This is often used alongside Granulocyte-Colony Stimulating Factor (G-CSF) to enhance white blood cell mobilization. Additionally, antibiotics and antifungals are prescribed to manage infections stemming from the immune deficiencies characteristic of WHIM syndrome.

Learn more about the FDA-approved drugs for WHIM Syndrome @ Drugs for WHIM Syndrome Treatment- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the WHIM Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• WHIM Syndrome Companies- NIAID, X4 Pharmaceuticals, and others.
• WHIM Syndrome Pipeline Therapies- X4P-001, Mavorixafor, and others.
• WHIM Syndrome Market Dynamics: WHIM Syndrome Market Drivers and Barriers
• WHIM Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about WHIM Syndrome Drugs in development @ WHIM Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 WHIM Syndrome Market Report Introduction
3 WHIM Syndrome Market Overview at a Glance
4 WHIM Syndrome Epidemiology and Market Forecast Methodology
5 Key Events
6 WHIM Syndrome Executive Summary
7 Disease Background and Overview: WHIM syndrome
8 Patient Journey
9 WHIM Syndrome Epidemiology and Patient Population
10 WHIM Syndrome Marketed Therapies
11 Emerging WHIM Syndrome Therapies
12 WHIM Syndrome: Seven Major Market Analysis
13 Key Opinion Leaders' Views
14 WHIM Syndrome SWOT Analysis
15 WHIM Syndrome Unmet Needs
16 WHIM Syndrome Market Access and Reimbursement
17. The United States
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Periodontal disease market- https://www.delveinsight.com/report-store/periodontal-disease-market
Surgical energy instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
NK Cell Therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.